Company profile
Tonix Pharmaceuticals Holding Corp.
NASDAQ: TNXP · Healthcare · Biotechnology
#598 of 1,418 Healthcare companies by revenue71st-percentile growth
EA Score
45DFH 45DQ 39GM —SS 66
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, revenue growth (YoY) · ↓ disclosure history, Piotroski F
Methodology →Revenue TTM
$29.1M
Rev growth YoY (TTM)
+196.0%
Net income (FY)
-$124.0M
Employees
142
as of 2026-08-13
Market cap
$190.8M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$13.1M$13.1M2025
Net income-$124.0M-$124.0M2025
Operating income-$125.7M-$125.7M2025
Total assets$277.2M$277.2M2025
Liabilities$32.0M$32.0M2025
Equity$245.2M$245.2M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Tonix Pharmaceuticals Holding Corp.’s revenue?
Tonix Pharmaceuticals Holding Corp. booked $13.1M in FY2025 revenue, growing 30% year over year — faster than most Healthcare companies we track, at a -946.2% net margin.
Peers · Healthcare
Microbix Biosystems Inc.60CNovo Integrated Sciences, Inc.——Mednow Inc.——Radnostix, Inc.51DLeveljump Healthcare Corp.——Spero Therapeutics, Inc.68BNeighbors
Morris →Key facts
CEOSeth Lederman
SectorHealthcare
IndustryBiotechnology
HeadquartersChatham, NJ
ExchangeNASDAQ: TNXP
Employees142
IPO date2012-05-10
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.